NCT03347786 Verapamil for Neuroprotection in Stroke
| NCT ID | NCT03347786 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Global Neurosciences Institute |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2017-04-20 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2017-04-20 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.
Eligibility Criteria
Inclusion Criteria: * Written informed consent * 18 years of age and over * Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia * Candidate for mechanical thrombectomy procedure * Onset of symptoms less than 8 hours * Measurable neurologic deficit (NIHSS ≥4) * Willingness to follow up with rehabilitation therapy * Anticipated life expectancy of at least 3 months Exclusion Criteria: * Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential) * Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min) * Thrombocytopenia (platelet count \<75,000/mm3) * History of intolerance to verapamil * Previous functional disability (modified Rankin \> 1) * Severe stroke (NIHSS\>22) * Stuporous or comatose * Unlikely to be available for 90 day follow-up
Frequently Asked Questions
Who can join the NCT03347786 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03347786 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03347786 currently recruiting?
Yes, NCT03347786 is actively recruiting participants. Visit ClinicalTrials.gov or contact Global Neurosciences Institute to inquire about joining.
Where is the NCT03347786 trial being conducted?
This trial is being conducted at Atlantic City, United States, Langhorne, United States, Upland, United States.
Who is sponsoring the NCT03347786 clinical trial?
NCT03347786 is sponsored by Global Neurosciences Institute. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.